Paper Details

  1. Home
  2. Paper Details

Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group.

Author: BerthouC, CahnJ Y, FrançoisS, GuyotatD, HarousseauJ L, IfrahN, JouetJ P, LamyT, LinassierC, PignonB, WitzF

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the efficacy and safety of a chemotherapy schedule similar to that used for acute myeloblastic leukemia (AML) patients in treating adult patients with acute lymphoblastic leukemia (ALL), specifically examining the complete remission (CR) rate, the value of intensive treatment stages, and the impact of recombinant granulocyte-macrophage-colony stimulating factor (rGM-CSF).
Paper Details　
Original Abstract of the Article :
Despite modern treatment programs, less than 20% of adult cases of acute lymphoblastic leukemia (ALL) are cured. For relapsing and/or refractory patients, use of high dose cytosine arabinoside (ara-C) and anthracyclin achieved a complete remission (CR) rate of up to a 75%. The aim of this study was ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/(sici)1097-0142(19991015)86:8<1496::aid-cncr16>3.0.co;2-#

データ提供：米国国立医学図書館（NLM）

Intensive Therapy for Acute Lymphoblastic Leukemia: A Desert of Hope

Acute lymphoblastic leukemia (ALL), a formidable foe in the vast desert of hematological malignancies, often presents a challenging treatment landscape. This study delves into the potential of a high-intensity treatment regimen, inspired by the approach used for acute myeloblastic leukemia (AML), in the context of adult ALL. The researchers aimed to evaluate the efficacy and safety of this intensive approach, investigating its impact on remission rates, tolerance, and the role of granulocyte-macrophage-colony stimulating factor (GM-CSF) support.

Intensive Therapy: A Double-Edged Sword in ALL Treatment

This study, like a caravan navigating a treacherous desert, reveals the complexities of intensive therapy for ALL. While the study demonstrated a high complete remission rate, the intense regimen also presented significant challenges, including neutropenia and infectious complications. These findings highlight the need for careful consideration of the risks and benefits of such aggressive treatment approaches.

Balancing Intensity and Safety in ALL Treatment

This research, like a beacon guiding us through the complexities of ALL treatment, underscores the importance of balancing intensity with safety. The study's findings suggest that while intensive therapy can be effective, careful monitoring and management of potential side effects are crucial for optimizing patient outcomes.

Dr. Camel's Conclusion

Intensive therapy, like a vast desert, can be a powerful tool for combating ALL, but it's not without its perils. This study underscores the need for careful navigation, balancing intensity with safety to ensure the best possible outcomes for patients facing this formidable foe. Further research is crucial to optimize these treatment strategies, ensuring that we can navigate the desert of ALL with greater success.

Date :
  1. Date Completed 1999-11-17
  2. Date Revised 2019-06-20
Further Info :

Pubmed ID

10526278

DOI: Digital Object Identifier

10.1002/(sici)1097-0142(19991015)86:8<1496::aid-cncr16>3.0.co;2-#

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.